Nancy Cox is a quantitative human geneticist with a long-standing research program focused on identifying and characterizing the genetic component to common human diseases and related traits. Her lab is computational and a major current research activity is in developing methods integrating genome function and genome variation and in applying these new methods to data on common diseases. Dr. Cox has been funded to develop and apply methods for the analysis of sequence data (for the 1000 Genomes Project) and of transcriptome data (for the GTEx -- Genotype Tissue Expression -- project), and to conduct genetic / genomic studies in type 2 diabetes and its complications, pharmacogenomics of anti-cancer agents, breast cancer, mesothelioma, and neuropsychiatric disorders including Tourette Syndrome, obsessive compulsive disorder, autism, bipolar disorder and schizophrenia. A major focus of future research will be applying novel integrative methods for analyzing data in BioVU, the biobank at Vanderbilt University, with DNA samples on more than 215,000 subjects linked to a high-quality electronic health record going back more than 20 years. Due to investments made by Vanderbilt University Medical Center, BioVU will have genome interrogation on more than 120,000 subjects by then end of 2017, permitting unprecedented investigations into how genome variation contributes to the entire medical phenome.